Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Novartis - Caught on Camera

Late Stage Trial Miss Leaves Adults with Myotonic Dystrophy Still Waiting for a First Approved Treatment

Novartis says its Phase 3 HARBOR trial of del-desiran missed its main goal in myotonic dystrophy type 1, a disease with no approved therapy.

Medical Daily

Global Market: European shares slip as oil surge fuels inflation fears; Novartis plunges

European shares slipped as surging oil prices raised inflation concerns amid escalating Middle East tensions and threats to Gulf energy infrastructure. The STOXX 600 fell 0.2%, while Germany and France declined. Novartis plunged after a second drug trial setback, whereas Sandoz gained on ambitious long-term growth targets. Investors monitored energy…

The Economic Times

Novartis Heart Drug Lowered a Genetic Risk Factor but Did Not Cut Heart Attacks or Strokes

Novartis says pelacarsen missed its main goal in an 8,323-patient late-stage trial, lowering Lp(a) without reducing cardiovascular events.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

European shares subdued as surging crude sharpens focus on ECB rate path

European shares closed largely flat as higher oil prices and renewed US-Iran tensions raised inflation concerns, offsetting stronger euro zone economic data. Energy stocks gained, while Novartis fell after its cholesterol drug failed a key study. Investors also raised bets on further ECB rate hikes, including a possible December move.

The Economic Times

Global Market: European stocks subdued as oil surge fuels inflation, ECB rate hike bets

European shares were subdued on Monday as rising oil prices sparked by US-Iran tensions renewed inflation fears. Investors are closely monitoring the European Central Bank's upcoming interest rate decision, while a sharp decline in Novartis stock and German political uncertainty following regional elections further weighed on overall market sentiment.

The Economic Times

Adobe’s next boss joins a powerful club: Meet the Indian-origin CEOs running the world’s biggest companies

Adobe’s next CEO Anil Chakravarthy is joining a powerful club. From Microsoft and Google to Chanel, FedEx and Micron, Indian-origin executives now run companies spanning technology, banking, luxury, pharmaceuticals and manufacturing. Here are the leaders occupying some of the biggest corner offices in global business.

The Economic Times

An Oral BTK Pill Cut Relapses in Two Phase Three MS Trials With Full Data Still Unreleased

Novartis says remibrutinib beat teriflunomide on relapse rates in two Phase 3 MS trials, but has not released the underlying numbers.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

An Oral Pill for Relapsing MS Beat a Standard Drug in Two Trials with No Figures Released

Novartis says remibrutinib beat teriflunomide in two Phase 3 MS trials. The company released no numbers and the data are unpublished.

Medical Daily

Two Drugmakers Have Paused Autoimmune CAR T Cell Trials After Three Deaths from a Severe Immune Reaction

Novartis paused eight autoimmune CAR T trials after three severe immune reactions, and Bristol Myers Squibb paused enrollment in its program.

Medical Daily

Dow Falls 419 Points as Bond Yields Rise: Stock Market Today

The energy shock is not going away, and it's only making things worse for the bond market, as well as the stock market, over the long term.

Kiplinger

First baby identified through Scotland’s SMA pilot has started treatment

The condition affects an average of three to four babies a year in Scotland and about 70 infants a year across the UK.

Evening Standard

Novartis Pulls One Lot of Brand Name Diovan After Tablets Failed a Dissolution Test Tied to Potency

Novartis recalled one lot of Diovan 160 mg after tablets failed dissolution testing. Check lot AV5913C and do not stop your medication.

Medical Daily

Prostate Cancer Patients Just Gained a New Radioligand Option, but Only Licensed Centers Can Give It

FDA expanded Pluvicto to hormone-sensitive metastatic prostate cancer, nearly doubling eligibility. Only licensed nuclear medicine centers can administer it.

Medical Daily

Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?

Health minister Mark Butler confirms Ocrevus, Kesimpta and Lemtrada will stay subsidised amid questions about the Pharmaceutical Benefits Scheme

The Guardian - AU

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Carrie Ann Inaba's Delayed Diagnosis Highlights the Hidden Struggle of 4 Million Americans with Sjögren Disease

Sjögren disease affects 4 million Americans — 90% women — but takes an average of 4+ years to diagnose. Carrie Ann Inaba's story explains why, and what to do about it.

MarketBeat

3 European Stocks to Carry Investors Through the Back Half of 2026

European stocks are outpacing the S&P 500 in 2026, and ArcelorMittal, Arm Holdings, and Novartis are three Euro Stoxx 50 components with index-beating returns.

Bangkok Post

“Voice for Her Power” Unites Sectors to Advance Equity in Breast Cancer Care

The “Voice for Her Power: Empowered by Hope to Overcome Breast Cancer” alliance, led by the Thai Breast Cancer Community; Sabina Public Company Limited; The Sukosol Hotel Bangkok; and Novartis (Thailand) Limited, organized a collaborative initiative to pass on the voice of hope and ignite societal awareness about the importance…

The Guardian - UK

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand…

The Economic Times

Molecule glue drugs shake up cancer care, draw big money

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therapies.

MarketBeat

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

The Guardian - UK

First malaria drug for babies is approved in ‘major public health milestone’

WHO prequalification of Coartem Baby means newborns can be safely treated rather than using medication for older children

The Independent UK

Carrie Ann Inaba shares health update after suffering medical emergency on flight

The ‘DWTS’ judge was on a flight to New York City for a campaign for her pharmaceutical company, Novartis

Evening Standard

Scotland becomes first part of UK to screen babies for rare muscle disease

All parents will now be offered spinal muscular atrophy screening for their newborns.

Fortune

Exclusive: Oro Labs, which is using AI to streamline companies' procurement processes, raises $100 million in fresh venture capital funding

Goldman Sachs Equity Growth and Brighton Park Capital lead the funding round for the company, which says it can reduce procurement process times from weeks to days or hours

1 2 3 4 5

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations